Geron Corporation (NASDAQ:GERN) — Market Cap & Net Worth
Market Cap & Net Worth: Geron Corporation (GERN)
Geron Corporation (NASDAQ:GERN) has a market capitalization of $828.79 Million ($828.79 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9771 globally and #2679 in its home market, demonstrating a -14.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Geron Corporation's stock price $1.29 by its total outstanding shares 642473409 (642.47 Million). Also see Geron Corporation balance sheet assets for a full breakdown of the balance sheet.
Geron Corporation Market Cap History: 2015 to 2026
Geron Corporation's market capitalization history from 2015 to 2026. Data shows change from $3.11 Billion to $828.79 Million (-8.19% CAGR). Also see GERN operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Geron Corporation is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #278 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1021 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.04% | #164 of 263 |
Weight: Geron Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Geron Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Geron Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GERN share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.61x
Geron Corporation's market cap is 4.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.33 Billion | $6.16 Million | -$29.54 Million | 215.83x | N/A |
| 2017 | $1.16 Billion | $1.06 Million | -$27.92 Million | 1085.87x | N/A |
| 2018 | $642.47 Million | $1.07 Million | -$27.02 Million | 602.70x | N/A |
| 2019 | $873.76 Million | $460.00K | -$63.55 Million | 1899.49x | N/A |
| 2020 | $1.02 Billion | $253.00K | -$75.62 Million | 4037.68x | N/A |
| 2021 | $783.82 Million | $1.39 Million | -$116.11 Million | 562.68x | N/A |
| 2022 | $1.55 Billion | $596.00K | -$141.90 Million | 2608.70x | N/A |
| 2023 | $1.36 Billion | $237.00K | -$184.13 Million | 5719.91x | N/A |
| 2024 | $2.27 Billion | $76.99 Million | -$174.57 Million | 29.54x | N/A |
| 2025 | $848.06 Million | $183.88 Million | -$85.78 Million | 4.61x | N/A |
Competitor Companies of GERN by Market Capitalization
Companies near Geron Corporation in the global market cap rankings as of September 18, 2026. Review GERN goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Geron Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Geron Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Geron Corporation's market cap moved from $3.11 Billion to $ 828.79 Million, with a yearly change of -8.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $828.79 Million | -2.27% |
| 2025 | $848.06 Million | -62.71% |
| 2024 | $2.27 Billion | +67.77% |
| 2023 | $1.36 Billion | -12.81% |
| 2022 | $1.55 Billion | +98.36% |
| 2021 | $783.82 Million | -23.27% |
| 2020 | $1.02 Billion | +16.91% |
| 2019 | $873.76 Million | +36.00% |
| 2018 | $642.47 Million | -44.44% |
| 2017 | $1.16 Billion | -13.04% |
| 2016 | $1.33 Billion | -57.23% |
| 2015 | $3.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Geron Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $828.79 Million USD |
| MoneyControl | $828.79 Million USD |
| MarketWatch | $828.79 Million USD |
| marketcap.company | $828.79 Million USD |
| Reuters | $828.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more